Login / Signup

Pre-treatment comorbidities, C-reactive protein and eosinophil count, and immune-related adverse events as predictors of survival with checkpoint inhibition for multiple tumour entities.

Tarun MehraKanchan DongreMaria BoesingPatricia FreiClaudia SuenderhaufAlfred ZippeliusJoerg D LeuppiAndreas WickiAnne B Leuppi-Taegtmeyer
Published in: Cancer medicine (2023)
We found an independent association between irAE occurrence and improved overall survival in a real-life cohort spanning multiple tumour entities and treatment regimens. Pre-treatment comorbidities, CRP and eosinophil count represent potential markers for predicting treatment response.
Keyphrases
  • risk assessment
  • dna damage
  • peripheral blood
  • smoking cessation
  • combination therapy